Thermo Fisher Scientific (NYSE:TMO) Stock Rating Upgraded by Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Thermo Fisher Scientific (NYSE:TMO – Free Report) from a hold rating to a buy rating in a research report released on Saturday morning.

A number of other equities analysts also recently issued reports on TMO. UBS Group lifted their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research note on Thursday, July 24th. Robert W. Baird lifted their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Barclays increased their target price on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an “equal weight” rating in a report on Thursday, July 24th. William Blair began coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an “outperform” rating on the stock. Finally, Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a report on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $593.00.

View Our Latest Report on TMO

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $493.05 on Friday. The stock has a market capitalization of $186.18 billion, a price-to-earnings ratio of 28.52, a PEG ratio of 2.63 and a beta of 0.75. The stock’s 50 day moving average price is $454.36 and its two-hundred day moving average price is $453.50. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific has a 52-week low of $385.46 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the prior year, the company earned $5.37 earnings per share. The company’s quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts predict that Thermo Fisher Scientific will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.95%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the sale, the chief executive officer owned 115,174 shares in the company, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,896 shares of company stock worth $13,603,438. Insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Centaurus Financial Inc. increased its stake in Thermo Fisher Scientific by 8.0% in the second quarter. Centaurus Financial Inc. now owns 7,176 shares of the medical research company’s stock valued at $2,910,000 after acquiring an additional 534 shares during the last quarter. MASTERINVEST Kapitalanlage GmbH purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth about $1,148,000. Stance Capital LLC bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $1,309,000. Pathway Financial Advisers LLC raised its holdings in shares of Thermo Fisher Scientific by 7.7% during the 2nd quarter. Pathway Financial Advisers LLC now owns 1,492 shares of the medical research company’s stock valued at $605,000 after buying an additional 107 shares in the last quarter. Finally, North Dallas Bank & Trust Co. purchased a new position in shares of Thermo Fisher Scientific during the second quarter worth approximately $437,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

About Thermo Fisher Scientific

(Get Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

See Also